aTyr Pharma, Inc. ATYR
aTyr Pharma, Inc. (Nasdaq: ATYR) is a respiratory drug developer. Its lead program, efzofitimod, is in Phase 2 for systemic sclerosis-associated interstitial lung disease (Phase 2 EFZO-CONNECT); pulmonary sarcoidosis new Phase 3 planned. Its next catalyst on record is efzofitimod (EFZO-CONNECT, SSc-ILD): Topline data (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: efzofitimod (EFZO-CONNECT, SSc-ILD) — Topline data (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| efzofitimod | pulmonary sarcoidosis (EFZO-FIT Phase 3 missed primary endpoint; new Phase 3 planned, protocol submitted to IND, not yet enrolling) | protein/peptide | Phase 3 |
| efzofitimod | SSc-ILD (EFZO-CONNECT, enrollment complete, 23 patients) | protein/peptide | Phase 2 |
| ATYR0101 | fibrotic diseases | protein/peptide | Pre-clinical |
Recent results and decisions
- Aug 7, 2026completed enrollment Enrollment completed in the Phase 2 EFZO-CONNECT study in SSc-ILD with 23 patients enrolled.
Enrollment completed in the Phase 2 EFZO-CONNECT™ study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited or diffuse SSc-ILD.
Filing - May 11, 2026n/a After a Type C meeting, FDA supported FVC and KSQ-L as meaningful endpoints and aTyr will pursue a new Phase 3 study (C-006) in restrictive pulmonary sarcoidosis.
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback; Company to pursue with new Phase 3 study (C-006)
Filing - Nov 6, 2025missed Phase 3 EFZO-FIT (n=268) missed primary endpoint of change in daily oral corticosteroid dose at week 48; 5.0 mg/kg showed benefit on KSQ-Lung, fatigue and steroid withdrawal secondaries.
The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.